Shots:

• The results from a P-II investigator-sponsored trial evaluate cabozantinib + pembrolizumab in patients with recurrent or metastatic HNSCC
• The trial met its 1EPs of ORR (54%) as per RECIST version 1.1, overall clinical benefit rate (91%), 1yr. PFS rate was 54.0% at a median follow-up of 10.6mos. and m-PFS was 14.6mos. Additionally, 1yr. OS rate (68.4%) with m-OS of 22.3mos.
• In the 17 patients with a PD-L1 CPS ≤20 & ≥20, the 1yr. OS rate was (54.9% & 83.6%) with m-OS (14.6mos. & 32.9mos.), 89% of patients had received prior radiation therapy and all had received prior CT, dose reductions were reported in 47.2% of patients, and AEs leads to discontinuation in 25.0% of patients

Ref: Exelixis | Image: Exelixis